Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 1Meningioma 1Medulloblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Filgrastim 19Temozolomide 18Cyclophosphamide 16Carboplatin 15Etoposide 12Vincristine 11Peripheral Blood Stem Cell Transplantation 10Cisplatin 10Radiotherapy 9Irinotecan 9Thiotepa 8Granulocyte Colony-Stimulating Factor 7sonidegib 5Methotrexate 5sargramostim 4Vorinostat 4Magnetic Resonance Spectroscopy 4Lomustine 4Chemotherapy, Adjuvant 4Carmustine 4etoposide phosphate 3Topotecan 3Radiation 3Platinum 3Paclitaxel 3Oxaliplatin 3O(6)-benzylguanine 3Melphalan 3HhAntag691 3Granulocyte-Macrophage Colony-Stimulating Factor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Medulloblastoma × arginyllysine × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡